Introduction
Treatment of even mildly elevated blood pressure (BP) reduces cardiovascular morbidity and mortality. 1 As mild-to-moderate essential hypertension in general is devoid of symptoms, the therapyinduced side effects may outweigh the beneficial effects of treatment. 2 These side effects not only relate to easily recognisable adverse events, but also include all other possible negative effects on quality of life which may result in non-compliance and ineffective treatment. 3 Consequently, on comparison of antihypertensive agents, efficacy of BP control as well as effects on quality of life should be evaluated. 4 In 1986, Croog et al 5 showed that the effects of antihypertensive agents on quality of life can be meaningfully assessed with validated quality of life questionnaires. From that publication on several studies on the effects of antihypertensive drugs on bendrofluazide neither in the intention-to-treat nor in the efficacy analysis any difference was found in quality of life variables, such as Health Status Index, somatic symptoms, anxiety, depression, total psychiatric morbidity, cognitive symptoms and hostility score. Compared to baseline the Health Status Index improved (P Ͻ 0.05) during bisoprolol. None of the other investigated quality of life variables changed compared to baseline. No patients dropped out during bisoprolol or bendrofluazide treatment. Although, the total number of reported adverse events appeared lower during bendrofluazide than during bisoprolol treatment, it is unclear whether drug related adverse events also differ between the two drugs. Conclusions: At equipotent antihypertensive dosages, the effect of an 8-week treatment on quality of life does not differ between the selective ␤ 1 -blocker bisoprolol and the thiazide diuretic bendrofluazide. quality of life have been published. It has been shown that quality of life is lower during treatment with the non-selective ␤-blocker propranolol than with selective ␤ 1 -blockers. [6] [7] [8] Several studies also show that quality of life with selective ␤ 1 -blockers cannot be differentiated from that with angiotensinconverting enzyme (ACE)-inhibitors, 7,9-14 and calcium antagonists. [15] [16] [17] Compared to ␤-blockers and ACE inhibitors, quality of life with diuretics has not been studied extensively, 4, 9 and conclusions were inconsistent. 18 Some studies showed a negative impact on quality of life of thiazide diuretics given as monotherapy, 18 or added to existing antihypertensive treatment. 5, 19 A negative impact has been reported particularly on sexual function. [18] [19] [20] [21] [22] However, much of the criticism on quality of life with thiazides is based on the use of (too) high doses. Indeed, increasing the dose of a thiazide diuretic increases the adverse effects but not its antihypertensive activity. 23 Although the literature on the effect of low-dose diuretics on the quality of life is limited, data from the SHEP study indicate that lowdose diuretics are unlikely to harm the overall quality of life in hypertensive patients. 24 The TOMHS study even suggests that quality of life improves during low-dose chlorthalidone therapy. 25 Despite this increase in overall quality of life, low-dose chlorthalidone negatively influenced sexual function. 26 Both ␤-blockers and thiazide diuretics are frequently used in hypertension and are recommended as preferred initial drug therapy. 1, 27 However, only few studies compared their effects on quality of life. 20, 25 To date, no comparison has been made between the highly selective ␤ 1 -blocker bisoprolol and the thiazide diuretic bendrofluazide. The aim of the present study was to compare the effects on quality of life of bisoprolol and bendrofluazide.
Patients and methods

Patients
Eighty-seven patients with newly diagnosed or preexisting hypertension were recruited from six general practice centres. Six patients were excluded (Table 1) , leaving 81 patients for randomisation. Blood pressure inclusion criteria were (i) a mean sitting diastolic BP (DBP) у95 and р120 mm Hg measured on two consecutive visits with a 2-week interval, and (ii) a difference between these two readings of 5 mm Hg or less. The patient was excluded if systolic BP (SBP) exceeded 220 mm Hg or DBP exceeded 120 mm Hg. Other major exclusion criteria were relevant cardiovascular and pulmonary disease, impaired renal function, insulin-dependent diabetes mellitus, hyperthyroidism, pregnancy and known intolerance to ␤-blockers or thiazides or a history of gout.
Study design
This study featured a multi centric, randomised, double-blind, two-way crossover design ( Figure 1 ). The study started with a single-blind run-in period. During this period, all antihypertensive therapy was withdrawn and patients received a placebo tablet once daily (o.d.). If after 4 weeks patient's BP did not meet the inclusion criteria, placebo was continued for another 2 weeks. Patients not complying with the inclusion criteria after 6 weeks of placebo were excluded from randomisation. During the active treatment periods (8 weeks each), patients received either bisoprolol 5 mg o.d. or bendrofluazide 2.5 mg o.d. using the double dummy technique. Up to week 6 of each treatment period, the dose could be doubled once if the DBP exceeded 95 mm Hg or DBP had not decreased by 10 mm Hg.
After the first active treatment period, patients were 'washed-out' on placebo. Washout was considered successful if (i) DBP measured at two consecutive visits did not differ more than 5 mm Hg, and (ii) the mean of these two measurements did not differ from randomisation by more than 5 mm Hg. Washout lasted at least 4 weeks. If after 6 weeks the washout criteria were not met, patients were excluded.
Blood pressure and quality of life assessments were performed at the end of the run-in period and at the end of each crossover period. On each occasion, all assessments were made at the end of the dosing interval (ie, approximately 24 h after the last drug intake).
The study was approved by the local Ethics Committee and was conducted in accordance with the declaration of Helsinki. All patients gave their written informed consent before entering the trial.
Methods
Blood pressure and heart rate were measured in sitting position. Data are means of three consecutive measurements made at a 1-min interval. Heart rate was measured by counting the radial pulse. Blood pressure was measured using a mercury sphygmomanometer. DBP was defined at Korotkoff's phase V sound.
Quality of life was assessed using a self-administered quality of life questionnaire described by Bulpitt and Fletcher. 28 This questionnaire scores for seven variables: health status index (HSI), total psychiatric morbidity, anxiety, depression, somatic symptoms, cognitive symptoms and hostility. Except for HSI, a lower score indicates a better quality of life.
Adverse events were spontaneously reported by the patient or recognised by the clinician.
Statistical analysis
Demographic data are presented as mean ± s.d. All other data are presented as mean ± s.e.m. Effects of the drugs were compared with the Koch procedure for the two-way crossover design, 29 using the unpaired Student's t-test. This procedure tests for direct effects (ie, treatment effects) as well as for indirect effects (ie, carry-over and period effects). Comparison with baseline was performed using the paired Student's t-test. Baseline was defined as the assessment at the end of the run-in period. Efficacy analysis was done on all patients with complete data at the end of the trial. An intention-to-treat analysis was performed according to the 'last observation carried forward' principle on all randomised subjects. 30 Ninety-five percent confidence intervals were calculated for the differences in quality of life scores between both treatments. A P Ͻ 0.05 was considered statistically significant.
Results
After randomisation, two patients dropped out during washout between the two active treatment periods (Table 1) . Seventy-nine patients (33 males and 46 females) completed the study. Twenty-two of them were active smokers, 37 non-smokers and 20 ex-smokers. Their age averaged 61 ± 24 years, their weight 70 ± 14 kg and their height 166 ± 12 cm. Patients mean duration of hypertension was 2.9 ± 3.7 years. Thirty-five patients (44%) had never been treated for hypertension before. Forty-four (56%) had been using antihypertensive treatment as monotherapy or as a combination therapy. Six patients were excluded from efficacy analysis because of incomplete data and another 12 patients for lack of complete washout between the two treatment periods. This leaves 61 patients (27 males, 34 females) for the efficacy analysis. The intention-totreat analysis was performed on all randomised patients (n = 81). In the efficacy analysis, no period or carry-over effects were present. Also in the intention-to-treat analysis, no period or carry-over effects were found for any of the investigated haemodynamic or quality of life parameters, except for a period effect for Health Status Index score (P = 0.01).
At randomisation, BP and heart rate averaged 160 ± 2/103 ± 1 mm Hg and 81 ± 2 beats/min, respectively. Decrease in BP did not differ between bisoprolol and bendrofluazide. The decrease (P Ͻ 0.001) vs baseline in SBP and DBP averaged 10 ± 2/13 ± 1 mm Hg with bisoprolol and 9 ± 2/11 ± 1 mm Hg with bendrofluazide. Bisoprolol reduced heart rate more (P Ͻ 0.001) than bendrofluazide (9 ± 2 beats/min and 3 ± 1 beats/min, respectively). The average dose of bendrofluazide used was 3.2 mg once daily, that of bisoprolol was 5.9 mg once daily in the efficacy analysis (n = 61). Body weight did not change throughout the study.
Results on quality of life parameters in the efficacy analysis are shown in Table 2 . Neither in the efficacy analysis nor in the intention-to-treat analysis bisoprolol and bendrofluazide differed for any of the investigated quality of life variables. Compared to baseline the HSI improved (P Ͻ 0.05) during bisoprolol intake. None of the other investigated quality of life variables changed compared to baseline.
Of all patients who completed the study, 28 patients reported a total number of 33 adverse events during active treatment: 21 adverse events were reported during bisoprolol and 12 during bendrofluazide (Table 3) .
Discussion
For research purposes, quality of life should be clearly defined. 6 As health is not only determined by the absence of disease, but by the presence of physical, mental and social well-being, the term 'quality of life' refers to the physical, psychological and social domains of health. 31 To measure quality of life, each of these domains has to be assessed. 31 The quality of life questionnaire used in the present study has been developed by Bulpitt and Fletcher. 28 This questionnaire covers the three above-mentioned domains of health and has previously been shown to meet the necessary criteria of coverage, validity, repeatability and responsiveness. 28, 31 Regarding the study design of quality of life trials, in general, a randomised, double-blind, placebocontrolled, parallel-group design is preferred. 4, 28 This design requires a large number of patients (150-200) per treatment group, owing to the variability of the data collected. 28 In a previous crossover study, differences in quality of life scores between ketanserin and placebo have been obtained with only 17 patients. 32 In the present study, efficacy analysis was performed on 61 patients. Quality of life trials should last sufficiently long, 4, 28 in order to allow for adaptation to side effects. In addition, side effects may diminish or disappear after some weeks. Hjemdahl and Wiklund suggest a minimum of 12 weeks. 4 In the present study, it cannot be excluded that results on quality of life might be influenced by the relative short treatment period (8 weeks). When a crossover design is used, which has an advantage in terms of power, carry-over and period effects have to be taken into account. 4, 28 In the present trial, no carry-over effects were found. A period effect was only observed in the intention-to-treat analysis for the Health Status Index. However, in contrast to a carry-over effect, using the Koch analysis for crossover design, a period effect does not limit the interpretation of treatment effect.
Quality of life with antihypertensive drugs should be compared at equipotent antihypertensive dosages. 4 As in the present trial bisoprolol and bendrofluazide were equally effective in reducing systolic and diastolic BP, between-drug comparisons for effects on quality of life are justified. In the present trial, no difference was observed between bisoprolol and bendrofluazide in their effects on quality of life. However, a type 2 error cannot be excluded. By increasing the number of patients in the study, statistical significance might be reached. But would that statistical difference be of clinical relevance? Hjemdahl and Wiklund consider a change of 5% or more clinically relevant. 4 Applying these criteria to the present study, the difference in Health Status Index and anxiety between bisoprolol and bendrofluazide would not be of clinical relevance. For all other quality of life variables, the score would suggest a better quality of life with bisoprolol than with bendrofluazide. The present study did not show statisti- ‫ء‬Baseline defined as the last assessment before randomisation. †P Ͻ 0.05 compared to baseline. Bi, bisoprolol; Be, bendrofluazide; 95% CI, 95% confidence interval. For Health Status Index a higher score, for all other variables a lower score means a better quality of life. cal difference. This is in line with the TOMHS study, showing that both a selective ␤-blocker (acebutolol) and a diuretic (chlorthalidone) improved several quality of life variables vs placebo, while no differences were observed between these treatments. 25 Also the TAIM Study, another large trial, did not find any difference in the effects on quality of life between chlorthalidone and atenolol. 20 In the present study, compared to baseline, only HSI improved during bisoprolol treatment. Since participation in a clinical trial itself may result in better quality of life scores, comparison with baseline measurements might lead to incorrect conclusions and should therefore be interpreted with caution. 11, 12, 25, 33 As no placebo group was included in the present study, absolute effects of the drugs on quality of life cannot be assessed. No difference in quality of life was found between bisoprolol and the ACE-inhibitor enalapril, 10,34 the calcium antagonists verapamil, 34 and nifedipine, 15 and the combined diuretic altizide/spironolactone. 34 A relation between the use of ␤-blockers and the occurrence of depression has been suggested in the past. 6, 35 As in a previous study with bisoprolol 15 no obvious change in depression score was observed during bisoprolol in the present study. Little is known about bendrofluazide and quality of life. Between low-dose bendrofluazide (2.5 mg o.d.) and captopril, no difference in cognition was observed. 36 In the present study, no patients dropped out during active treatment. This suggests that both drugs were well tolerated. Higher doses of bendrofluazide have been associated with adverse clinical effects. 23 As shown in the present study, these appear to be avoided by the use of lower doses. Nightmares, 37 dizziness, 6 and tiredness, 10 have been reported as side effects of classic ␤-blockers. In the present study only one patient reported dreams during bisoprolol. Although tiredness has also been reported with bisoprolol, 10, 15, 34 it was not reported more frequently than during treatment with the ACE-inhibitor enalapril, 10 and the calcium antagonist nifedipine. 15 In the present study tiredness appeared to be more frequently reported during bisoprolol than during bendrofluazide treatment. Although the total number of reported adverse events appeared lower during bendrofluazide than during bisoprolol, it is unclear whether drug related adverse events also differ between the two drugs.
It can be concluded that at equipotent antihypertensive dosages, the effect of an 8-week treatment on quality of life does not differ between the selective ␤ 1 -blocker bisoprolol and the thiazide diuretic bendrofluazide.
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